Andros Pharmaceuticals Co.,Ltd (6917) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of Andros Pharmaceuticals Co.,Ltd stock TWD 17.54, price TWD 29.95, that is 41.4% below the price, quality 32 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Andros Pharmaceuticals Co.,Ltd
6917 · TWOFar too expensive (fair value 41% below the price) and weak company.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
12‑month range 20.25 TWD – 43.60 TWD · fair‑value band 13.15 TWD – 21.92 TWD · the 29.95 TWD price screens above the 17.54 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Andros Pharmaceuticals Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies.
Show moreShow less
The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment of Osteoarthritis; and siRNA, an anti-sense oligonucleotide and DNA candidate.
Its preclinical phase products are APC310 and APC501 for anesthesia to intravenous catheter placement and venipuncture; and APC401, a special emulsified solution for anesthesia of post-surgery pain.
The company offers LALP cream for dermal analgesic applications; iMinos solution for Alopecia Androgenetica; and T4 endonuclease V. Andros Pharmaceuticals Co.,Ltd was founded in 2008 and is based in Zhubei, Taiwan.
Stock analysis
Andros Pharmaceuticals Co.,Ltd (6917) currently trades at 29.95 TWD, while our estimate is 17.54 TWD, 41% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 13.15 TWD (bear) to 21.92 TWD (bull), the price of 29.95 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Andros Pharmaceuticals Co.,Ltd reported revenue of 5.5M TWD in FY2025 versus 13.3M TWD in FY2021, a compound −19.7%/yr. Reported net income was −53.8M TWD in FY2025.
Key figures
Market cap 1.8B TWD (≈ $55.6M) Micro · EPS (TTM) −0.6300 TWD · Return on assets (EBIT) −18.1% (5-year average) · Free cash flow −46.4M TWD · Net cash 16.8M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (medium confidence).
What moves the price
The share trades about 31% below its 52-week high and 48% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −41%, 6917 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Andros Pharmaceuticals Co.,Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Price/FCF by industry
- Debt-to-equity by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Taiwanese Stocks
- Valuation of the Taiwan market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs 6917 |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs 6917 |
| Samsung Biologics Co 207940 | 1,414,000 KRW | 1,552,100 KRW | +10% | vs 6917 |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs 6917 |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs 6917 |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs 6917 |
| BeOne Medicines AG 6160 | HK$247.40 | HK$152.92 | −38% | vs 6917 |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs 6917 |
| Celltrion, Inc 068270 | 213,000 KRW | 74,945 KRW | −65% | vs 6917 |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs 6917 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Andros Pharmaceuticals Co.,Ltd (6917) overvalued or undervalued?
What is the fair value of 6917?
What is the quality score of 6917?
What is the price target for Andros Pharmaceuticals Co.,Ltd (6917)?
What is the Andros Pharmaceuticals Co.,Ltd stock forecast for 2026?
What is the intrinsic value of Andros Pharmaceuticals Co.,Ltd (6917)?
Is Andros Pharmaceuticals Co.,Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 6917?
How much is Andros Pharmaceuticals Co.,Ltd worth?
What do the bullish and bearish scenarios say about 6917?
How far is 6917 from its 52-week high?
Which stocks are comparable to Andros Pharmaceuticals Co.,Ltd?
Is Andros Pharmaceuticals Co.,Ltd stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Andros Pharmaceuticals Co.,Ltd (6917)?
What should I pay attention to with Andros Pharmaceuticals Co.,Ltd right now?
Key figures of Andros Pharmaceuticals Co.,Ltd
How large is the market capitalisation of Andros Pharmaceuticals Co.,Ltd (6917)?
What are the earnings per share of Andros Pharmaceuticals Co.,Ltd (6917)?
What is the EBIT return on assets of Andros Pharmaceuticals Co.,Ltd (6917)?
How much free cash flow does Andros Pharmaceuticals Co.,Ltd (6917) generate?
How much net cash does Andros Pharmaceuticals Co.,Ltd (6917) hold?
Watch Andros Pharmaceuticals Co.,Ltd in the live analysis
One click puts Andros Pharmaceuticals Co.,Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.